The WHO Emergency Use Listing Procedure (EUL) is a risk-based procedure for assessing and listing unlicensed vaccines, therapeutics and in vitro diagnostics with the ultimate aim of expediting the availability of these products to people affected by a public health emergency. This will assist interested UN procurement agencies and Member States in determining the acceptability of using specific products, based on an essential set of available quality, safety, and efficacy and performance data.
The procedure is a key tool for companies wishing to submit their products for use during health emergencies.
The EUL concerns three product streams (vaccines, therapeutics and in vitro diagnostics), each of which has specific requirements for products to be eligible for evaluation under the EUL procedure.
The following criteria must be met:
More information can be found here.
The contact email for Vaccines EUL submissions and more information is whoeul@who.int
Instructions for manufacturers detailing the technical specifications for the documentary evidence can be found here.
The contact email for IVDs EUL submissions and more information is diagnostics@who.int